Visit hfsa.org/boardreview2020 to learn more.
The HFSA Virtual Board Certification Review 2020 content is based on the ABIM content blueprint for the certification examination in Advanced Heart Failure and Transplant Cardiology. It will be held over the course of 3 days (July 24, July 31, August 1) and include pre-recorded ondemand webinars.

This activity will use concise didactic presentations by national experts, case studies, and panel discussions. An audience response system (ARS) will be utilized throughout all presentations and to deliver ABIM style questions in designated session time. Additional question and answer periods with faculty will enabling attendees to drive the discussion of according to their most pressing clinical challenges. A reading list compiled for the activity contains additional references regarding guideline- and evidence- based therapy.

The following areas are addressed:

- Epidemiology and Causes of Heart Failure
- Pathophysiology of Heart Failure
- Evaluation of Heart Failure
- Management of Hospitalized Patients
- Management of Heart Failure
- Comorbidities or Coexisting Conditions
- Cardiac Surgery in Heart Failure
- Heart Transplant
- Mechanical Circulatory Support
- Pulmonary Arterial Hypertension
- Contemporary HF Management Topics

The program will be made up of the following components to allow attendees greater access to the content.

**PRE-RECORDED WEBINAR SERIES:**

**HEART FAILURE FUNDAMENTALS**

Available in early July, this pre-recorded, ondemand webinar series features the basics and can be completed at the attendee’s convenience.

**LIVESTREAM SESSIONS**

Three, non-consecutive days of livestreamed sessions (July 24, July 31, August 1) delivered by top experts in the field. Attendees should anticipate being online throughout to receive maximum value from these live sessions. If a livestream session must be missed due to other circumstances, all livestream sessions will be available for attendees to download and access approximately two weeks after the meeting concludes. Full agenda is available at hfsa.org/boardreview2020/program

**FACULTY “OFFICE HOURS”**

Post-meeting, virtual livestream Q&A panel taking place in September to allow attendees to ask last-minute questions prior to the examination in October.

**ADDITIONAL BONUS FEATURES**

In addition to the core program components, attendees will have access to the following:

- A question bank
- Recommended reading list
- Live polling, Q&A, and chat features available during the livestream days
- Chat with fellow attendees and faculty throughout the course of the meeting

**ABIM CERTIFICATION DEADLINES**

- **ABIM Certification Exam Date:**
  October 21, 2020

- **Registration Dates:**
  December 1, 2019 – June 15, 2020

- **Late Registration Dates:**
  June 16-28, 2020 (additional fees apply)

Visit [www.abim.org](http://www.abim.org) for additional information about the certification exam.
ABIM CERTIFICATION DEADLINES

This HFSA Virtual Board Certification Review 2020 has been designed based on the competencies identified with practice in the area of Advanced Heart Failure and Transplant Cardiology.

These competencies include epidemiology, causes and management of patients with HF, management of hospitalized patients, management of comorbidities, cardiac surgery in HF, medical management of the heart transplant patient and patients with mechanical circulatory support, and evaluation and management of patients with pulmonary arterial hypertension.

LEARNING OBJECTIVES

Upon completion of the activity, participants will demonstrate improved competence and ability to:

For the Certification Examination in Advanced Heart Failure and Transplant Cardiology:
1. Identify gaps in knowledge about advanced heart failure and transplant cardiology
2. Focus study efforts on filling identified knowledge gaps
3. Practice for the certification examination with ABIM-style multiple-choice test questions

For Clinical Practice:
1. Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure
2. Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms
3. Assess and follow the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers.
4. Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and implantable devices
5. Implement appropriate care strategies for patients undergoing chemotherapy or with pulmonary hypertension, heart failure with preserved ejection fraction, or cardiorenal syndrome.
6. Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression
7. Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care
8. Provide peri-operative management of heart failure patients undergoing cardiac transplantation or implantation of a mechanical circulatory device

Concise presentations by national experts will focus on blueprint content and will be augmented by board-review-type questions posed using an audience-response system.

CREDIT DESIGNATION

This HFSA Virtual Board Certification Review has been designed based on the competencies identified with practice in the area of Advanced Heart Failure and Transplant Cardiology.

These competencies include epidemiology, causes and management of patients with HF, management of hospitalized patients, management of comorbidities, cardiac surgery in HF, medical management of the heart transplant patient and patients with mechanical circulatory support, and evaluation and management of patients with pulmonary arterial hypertension.

Physicians
The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Heart Failure Society of America designates this live activity for a maximum of 17 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17 MOC points in the Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
FACULTY

CO-CHAIRS
Akshay S. Desai, MD, MPH, FHFA
Medical Director, Cardiomyopathy and Heart Failure Program, Advanced Heart Disease Section
Brigham and Women’s Hospital
Boston, MA

Jonathan Rich, MD, FHFA
Associate Professor of Medicine
Northwestern University, Feinberg School of Medicine
Medical Director, Mechanical Circulatory Support Program
Program Director, Advanced Heart Failure and Transplant Fellowship
Bluhm Cardiovascular Institute, Northwestern Memorial Hospital
Chicago, IL

Nancy Sweitzer, MD, PhD, FHFA
Professor of Medicine
Chief of Cardiology
Director, Sarver Heart Center
University of Arizona
Tucson, AZ

Mark Drazner, MD, MSc, FHFA
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor
University of Texas Southwestern Medical Center
Dallas, TX

James Fang, MD, FHFA
Professor of Medicine
Chief, Division of Cardiovascular Medicine
Executive Director, Cardiovascular Service Line
University of Utah
Salt Lake City, UT

Sadiya Khan, MD, MSc
Associate Professor of Medicine – Cardiology
Associate Professor of Preventive Medicine – Epidemiology
Northwestern University Feinberg School of Medicine
Chicago, IL

Michelle Kittleson, MD, PHD
Professor of Medicine
Director of Post Graduate Medical Education in Heart Failure and Transplantation
Director of Heart Failure Research
Cedars Sinai Medical Center
Beverly Hills, CA

Liviu Klein, MD, MS
Associate Professor of Medicine
Division of Cardiology, University of California San Francisco
Director, Cardiology Clinical Research
Director, Mechanical Circulatory Support & Heart Failure Device Program
University of California, San Francisco
San Francisco, CA

Eric Krieger, MD
Associate Professor of Medicine
Director, Seattle Adult Congenital Heart Service
Director, Adult Congenital Heart Disease Fellowship
Attending Physician, University of Washington Medical Center
University of Washington School of Medicine
Seattle Children’s Hospital
Seattle, WA

Meredith Brisco-Bacik, MD, MSCE
Associate Professor of Medicine
Director, Heart Failure Clinical Research
Advanced Heart Failure and Cardiac Transplantation
The Lewis Katz School of Medicine at Temple University
Philadelphia, PA

Daniel Burkhoff, MD, PhD
Columbia University
New York, NY

Jennifer Cowger, MD, MS
Medical Director of Mechanical Circulatory Support Program
Co-Director of the Cardiac Intensive Care Unit
Henry Ford Hospitals, Detroit Michigan
Associate Professor, Wayne State University
Detroit, MI

Akshay S. Desai, MD, MPH, FHFA
Medical Director, Cardiomyopathy and Heart Failure Program, Advanced Heart Disease Section
Brigham and Women’s Hospital
Boston, MA
FACULTY (CONTINUED)

**Gregory Lewis, MD**  
Section Head, Heart Failure  
Director, Cardiopulmonary Exercise Testing Laboratory  
Medical Director, Cardiac Transplantation Program  
Massachusetts General Hospital  
Boston, MA

**Sanjiv Shah, MD**  
Stone Professor of Medicine  
Director of Research, Bluhm Cardiovascular Institute  
Director, Northwestern HFpEF Program  
Division of Cardiology, Department of Medicine  
Northwestern University Feinberg School of Medicine  
Chicago, IL

**Jon Lomasney, MD**  
Associate Professor of Pathology  
Associate Professor of Pharmacology  
Feinberg School of Medicine of Northwestern University  
Chicago, IL

**Anju Nohria, MD, MSc**  
Associate Physician, Brigham and Women’s Hospital  
Assistant Professor of Medicine, Harvard Medical School  
Boston, MA

**Sean Pinney, MD**  
Director, Advanced Heart Failure and Transplantation Program,  
The Mount Sinai Hospital  
New York, NY

**Jonathan Rich, MD, FHFSFA**  
Associate Professor of Medicine  
Northwestern University, Feinberg School of Medicine  
Medical Director, Mechanical Circulatory Support Program  
Program Director, Advanced Heart Failure and Transplant Fellowship  
Bluhm Cardiovascular Institute, Northwestern Memorial Hospital  
Chicago, IL

**Joseph Rogers, MD**  
Chief Medical Officer  
Duke University Health System  
Professor of Medicine – Cardiology  
Duke University  
Durham, NC

**Nancy Sweitzer, MD, PhD, FHFSFA**  
Professor of Medicine  
Chief of Cardiology  
Director, Sarver Heart Center  
University of Arizona  
Tucson, AZ

**Jane Wilcox, MD, MSc, FHFSFA**  
Assistant Professor of Medicine  
Director, Myocardial Recovery Program  
Associate Director, T1 Center for Cardiovascular Therapeutics  
Bluhm Cardiovascular Institute  
Chicago, IL

**Clyde W. Yancy, MD, MSc, FHFSFA**  
Vice-Dean, Diversity & Inclusion  
Chief of Cardiology  
Professor of Medicine  
Professor, Medical Social Sciences  
Associate Director  
Bluhm Cardiovascular Institute  
Deputy Editor, JAMA Cardiology  
Chicago, IL

*Note: Faculty is subject to change and will be updated continuously up to the conference.*
HFSA VIRTUAL BOARD CERTIFICATION REVIEW 2020

- OnDemand Webinar Series: Heart Failure Fundamentals
- Pre-Meeting Webinar: Cardiac Transplantation – July 26, 2020 – 3:00 PM – 6:00 PM ET
- 2020 HFSA Board Certification Review Course – July 24, July 31-August 1, 2020
  » Day 1  |  July 31st: 11 AM – 6:00 PM ET
  » Day 2  |  August 1st : 11 AM – 5:45 PM ET
- Faculty “Office Hours” Virtual Live-Stream Panel – September 2020 (TBD)

PRE-RECORDED WEBINAR SERIES: HEART FAILURE FUNDAMENTALS

<table>
<thead>
<tr>
<th>TALE TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart Failure Epidemiology and Risk Factors</td>
<td>Sadiya Khan</td>
</tr>
<tr>
<td>Pathophysiology I: Cellular and Energetic Considerations</td>
<td>Daniel Burkhoff</td>
</tr>
<tr>
<td>Pathophysiology II: Hemodynamic, Structural, and Neurohormonal Considerations</td>
<td>Daniel Burkhoff</td>
</tr>
<tr>
<td>Diagnosis and Clinical Assessment</td>
<td>Mark Drazner</td>
</tr>
<tr>
<td>Device Therapy in Heart Failure</td>
<td>Liviu Klein</td>
</tr>
<tr>
<td>Cardio-Oncology for the Heart Failure Boards</td>
<td>Anju Nohria</td>
</tr>
<tr>
<td>Clinico-Pathologic Correlates in Heart Failure/ Images for the Heart Failure Boards</td>
<td>Jon Lomasney</td>
</tr>
</tbody>
</table>

VIRTUAL LIVE-STREAM MEETING: DAY 1
July 24, 2020 | 3 PM - 6 PM EST

<table>
<thead>
<tr>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 PM</td>
<td>2:00 PM</td>
<td>12:00 PM</td>
<td>Welcome and HFSA Introduction</td>
<td>Chairs</td>
</tr>
</tbody>
</table>

**Session I: Cardiac Transplantation**

<table>
<thead>
<tr>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 PM</td>
<td>2:30 PM</td>
<td>12:30 PM</td>
<td>Advanced Heart Failure: Defining the Phenotype and Patient Selection for Advanced Therapies</td>
<td>Nancy Sweitzer</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>3:00 PM</td>
<td>1:00 PM</td>
<td>Immunology: The Basics, PRA, Sensitization, Crossmatch</td>
<td>Sean Pinney</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>3:30 PM</td>
<td>1:30 PM</td>
<td>Rejection: Cellular and Antibody Mediated</td>
<td>Sean Pinney</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>4:00 PM</td>
<td>2:00 PM</td>
<td>Managing Immunosuppression and Drugs</td>
<td>Michelle Kittleson</td>
</tr>
<tr>
<td>5:30 PM</td>
<td>4:30 PM</td>
<td>2:30 PM</td>
<td>Heart Transplant, Clinical Outcomes and Complications</td>
<td>Michelle Kittleson</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>5:00 PM</td>
<td>3:00 PM</td>
<td>Adjourns</td>
<td></td>
</tr>
</tbody>
</table>
## VIRTUAL LIVE-STREAM MEETING: DAY 2
**July 31, 2020 | 11 AM - 6 PM EST**

<table>
<thead>
<tr>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 AM</td>
<td>10:00 AM</td>
<td>8:00 AM</td>
<td>Welcome</td>
<td>Chairs</td>
</tr>
<tr>
<td><strong>SESSION II: Key Issues in HF Management</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 AM</td>
<td>10:30 AM</td>
<td>8:30 AM</td>
<td>Hemodynamics in HF I</td>
<td>James Fang</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>11:00 AM</td>
<td>9:00 AM</td>
<td>Hemodynamics in HF II</td>
<td>James Fang</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>11:30 AM</td>
<td>9:30 AM</td>
<td>Drug Therapy for Chronic HF I: Focus on established therapies (ACE/ARB/Beta-blocker/MRA/Digoxin/Hydralazine+Nitrates)</td>
<td>Clyde Yancy</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>12:00 PM</td>
<td>10:00 AM</td>
<td>Drug Therapy for Chronic HF II: Focus on newer therapies (Sacubitril/Valsartan, Ivabradine, SGLT2 inhibitors)</td>
<td>Mark Drazner</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>12:30 PM</td>
<td>10:30 AM</td>
<td><strong>BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>1:45 PM</td>
<td>12:45 PM</td>
<td>10:45 AM</td>
<td>HFpEF: Epidemiology, Risk Factors, Diagnosis, Management (for the boards)</td>
<td>Sanjiv Shah</td>
</tr>
<tr>
<td>2:15 PM</td>
<td>1:15 PM</td>
<td>11:15 AM</td>
<td>Management of the Hospitalized HF Patient</td>
<td>Meredith Brisco-Bacik</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>1:45 PM</td>
<td>11:45 AM</td>
<td>Management of Common Arrhythmias in HF (including AF)</td>
<td>Liviu Klein</td>
</tr>
<tr>
<td>3:15 PM</td>
<td>2:15 PM</td>
<td>12:15 PM</td>
<td>Management of Comorbidities in Heart Failure</td>
<td>Meredith Brisco-Bacik</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>2:45 PM</td>
<td>12:45 PM</td>
<td><strong>BREAK</strong></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION III: Specific Heart Failure Syndromes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td>3:00 PM</td>
<td>1:00 PM</td>
<td>Specific Etiologies of HF I: Common Etiologies (CAD, ETOH, Peripartum, Myocarditis)</td>
<td>Akshay Desai</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>3:30 PM</td>
<td>1:30 PM</td>
<td>Specific Etiologies of HF II: Inherited HF syndromes (including HCM, ARVC, and LVNC)</td>
<td>Jane Wilcox</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>4:00 PM</td>
<td>2:00 PM</td>
<td>Specific Etiologies of HF III: Infiltrative Disorders and Restrictive Cardiomyopathy (Amyloidosis, Sarcoidosis, Hemochromatosis, Fabry)</td>
<td>Sanjiv Shah</td>
</tr>
<tr>
<td>5:30 PM</td>
<td>4:30 PM</td>
<td>2:30 PM</td>
<td>Q&amp;A ---- Overview</td>
<td>Chairs</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>5:00 PM</td>
<td>3:00 PM</td>
<td>Adjourns</td>
<td></td>
</tr>
</tbody>
</table>
### VIRTUAL LIVE-STREAM MEETING: DAY 3
**August 1, 2020 | 11 AM - 5:45 PM EST**

<table>
<thead>
<tr>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 AM</td>
<td>10:00 AM</td>
<td>8:00 AM</td>
<td>Welcome &amp; Q/A</td>
<td>Chairs</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>10:30 AM</td>
<td>8:30 AM</td>
<td>Cardiogenic Shock Management</td>
<td>Nancy Sweitzer</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>11:00 AM</td>
<td>9:00 AM</td>
<td>MCS I: Durable MCS Devices and Outcomes</td>
<td>Joseph Rogers</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>11:30 AM</td>
<td>9:30 AM</td>
<td>MCS II: Temporary Support Devices and ECMO for the Boards</td>
<td>Jennifer Cowger</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>12:00 PM</td>
<td>10:00 AM</td>
<td>MCS III: MCS Complications and Patient Management</td>
<td>Jennifer Cowger</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>12:30 PM</td>
<td>10:30 AM</td>
<td>MCS IV: Troubleshooting (with HARVI)</td>
<td>Daniel Burkhoff, Jennifer Cowger, Joseph Rogers, Nancy Sweitzer</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>1:30 PM</td>
<td>11:30 AM</td>
<td><strong>BREAK</strong></td>
<td></td>
</tr>
</tbody>
</table>

#### SESSION IV: Shock/MCS

#### SESSION V: Special Topics in HF

<table>
<thead>
<tr>
<th>ET Time</th>
<th>CT Time</th>
<th>PT Time</th>
<th>TALK TITLE</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:45 PM</td>
<td>1:45 PM</td>
<td>11:45 AM</td>
<td>Assessment of Functional Capacity including cardiopulmonary exercise testing</td>
<td>Gregory Lewis</td>
</tr>
<tr>
<td>3:15 PM</td>
<td>2:15 PM</td>
<td>12:15 PM</td>
<td>Adult Congenital Heart Disease for the HF Specialist</td>
<td>Eric Krieger</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>2:45 PM</td>
<td>12:45 PM</td>
<td>Issues in Chronic HF Disease Management (Biomarkers, Remote Monitoring, Lifestyle Interventions)</td>
<td>Akshay Desai</td>
</tr>
<tr>
<td>4:15 PM</td>
<td>3:15 PM</td>
<td>1:15 PM</td>
<td>Management of Valvular Heart Disease in Heart Failure</td>
<td>Jane Wilcox</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>3:45 PM</td>
<td>1:45 PM</td>
<td>Pulmonary Hypertension</td>
<td>Jonathan Rich</td>
</tr>
<tr>
<td>5:15 PM</td>
<td>4:15 PM</td>
<td>2:15 PM</td>
<td>Q&amp;A ---- Overview</td>
<td>Chairs</td>
</tr>
<tr>
<td>5:45 PM</td>
<td>4:45 PM</td>
<td>2:45 PM</td>
<td>Adjourns</td>
<td></td>
</tr>
</tbody>
</table>

### Faculty “Office Hours” Virtual Live-Stream Panel
**September 2020 TBD**

| ET Time  | CT Time  | PT Time  | TALK TITLE               | SPEAKER                                                        |
|----------|----------|----------|--------------------------|                                                               |
| TBD      | TBD      | TBD      | Special Office Hour - Q&A | Akshay Desai, Nancy Sweitzer, Jonathan Rich                   |